TRO9 Feb 2022 08:03
The issue really is that the CRO world is populated by different types of company.
There's the very large ones, who do pretty much everything, but often don't have the expertise, nor the inclination, to translate their data and help any partners develop to the next stage. And frankly, some are so big, they don't really care, because they just prioritise big pharma company work, who have their own in-house scientists to do that. The CRO is king now, choosy, and often having a larger market cap than many quite large pharma companies, and they are seldom short of work (at least in the last 5 years).
That's why you have consultants, who know how to progress drugs, to work with these CROs and interpret the data, ultimately contributing to an investigational new drug application, based on work generated elsewhere.
If you are a smaller or even medium size of business, this route is common.
I work with one outfit that has a MCap of 19Bil, and who cannot get their work into some of these CROs because they are too busy. They like me because I at least try and be helpful, and generally answer e-mails.
The issue with the more bespoke smaller CROs is that they are sometimes staffed by scientists, with poor customer/people skills, and/or limited in-house expertise, beyond a very defined specialism.
Suzy looks to be bringing consultant level expertise (she took 401 from the chemistry lab into a Phase 1, so no one can say she doesn't have this), and combining it with a data generation service, to provide a fairly comprehensive early-stage package.
Me, I think she will clean up here. When the shysters, who are not all that interested, are "swamped" with work, then her hand will be bitten off as soon as she plugs it.
Also, if there is an in-house development capability, say to a stage when you start safety testing, then you aren't waiting for Jeff to come back from Marbella to incubate his cells, in order to complete the work.
I imagine Suzy trying to run some assays with 301 and thinking "FFS - I could do this myself, next week if we had these poxy hEM3 cells".
A key aspect also is that Suzy is young and enthusiastic. She also has excellent inter-personal skills, and is really, really, really keen; so they are already 90% there.
Sign In
Follow the stocks
